All In MedTech

Device Trial Radar · NCT05870566

Pretreatment to Promote Graft Survival After Subsequent High-risk Corneal Transplantation [CrossCornealVision]

UV Light-mediated Corneal Crosslinking as (Lymph)Angioregressive Pretreatment to Promote Graft Survival After Subsequent High-risk Corneal Transplantation [CrossCornealVision]

Last checked: Nov 19, 2026Latest source record: Oct 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

110

Planned (sponsor's estimate)

Start

Nov 20, 2023

Primary completion

Sep 30, 2027

Study completion Sep 30, 2028

Sponsor

Lead sponsor
Claus CursiefenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Uniklinik Köln, Zentrum für Klinische Studien; Uniklinik Köln, Institut für Medizinische Statistik und Bioinformatik; German Federal Ministry of Education and Research
First posted
May 23, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial evaluates the effect of corneal crosslinking as pre-treatment before corneal transplantation. The goal is to improve graft survival by reducing pathological vessels through pre-treatment.

Conditions

  • Corneal Transplantation

Interventions

  • Corneal CrosslinkingDevice

    Riboflavin isotonic, 0,1 % Vitamin B2, with Dextran 20,0%, for epi-off procedure or Riboflavin isotonic 0,1% (Vitamin B2), 1,1% HPMC without Dextran for epi-off) 0.1% riboflavin-5-phosphate and 20% dextran T-500) will be applied to the cornea after epithelial debridement every 2 min for 10 minutes before irradiation and every 2 minutes during the course of a 10 minute exposure to 365 nm UV-A with an irradiance rate of 9 mW/cm2. This dose, mode and scheme of the intervention follows the internationally recognized "accelerated CXL protocol" (Elbaz et al. 2014). The data existing shows equivalent outcome regarding efficacy and safety compared to the standard protocol. To avoid any damage to the limbal stem cells, the limbus will not be irradiated during the procedure, as a CXL device (with maximal diameter of 11 mm) will be used. Furthermore, the limbal area will additionally be protected by a custom-cut LSC protection shield. (Protocol V04\_0 Page 45-46)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. First episode of endothelial graft rejectionTime frame: within 24 months after transplantation

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Charité - Universitätsmedizin Berlin, Klinik für Augenheilkunde

    Berlin, Germany · Recruiting

  • Universitätsklinikum Freiburg, Klinik für Augenheilkunde

    Freiburg im Breisgau, Germany · Recruiting

  • Klinik und Poliklinik für Augenheilkunde - Universitätsmedizin Rostock

    Rostock, Germany · Recruiting

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.